转移性激素敏感性前列腺癌的临床研究进展

Clinical progression of metastatic hormone-sensitive prostate cancer

近年来,随着新药研发以及相关临床试验的开展,转移性激素敏感性前列腺癌(mHSPC)在治疗手段方面发生了根本性变化。以雄激素剥夺疗法(ADT)为基础的联合治疗目前已成为mHSPC治疗的主要手段以及临床研究热点。虽然多种临床治疗方案使患者获得更多的选择,但同时也给泌尿肿瘤医师提出了更多的挑战。本文将结合最新的临床研究,综述当前mHSPC治疗的新进展,以期优化治疗选择使患者最大获益。

In recent years,with the development of new drugs and related clinical studies,a huge amount of changes have taken place in the treatment of metastatic hormone-sensitive prostate cancer(mHSPC).At present,combined therapy based on androgen deprivation therapy(ADT)has become the main therapy and research hotspot of mHSPC.While multiple clinical treatment options provide more choices for mHSPC patients,they also pose challenges for urological clinicians.In this review,we summarized the latest advances of mHSPC therapies and intended to provide optimizing treatment options for maximum benefit of patients.